Tonix Pharmaceuticals CEO Seth Lederman joins Proactive's Natalie Stoberman to announce the acquisition of Healion Bio, including its entire portfolio of next-generation antiviral technology assets.

Lederman said the acquired portfolio of infectious disease assets includes a class of potential broad-spectrum antiviral agents, TNX-3900, with a host-directed mechanism. Tonix said it plans to develop the TNX-3900 series of molecules as oral antivirals, either as monotherapy or in combination with other antivirals.

Proactive USA

+1 347-449-0879

na-editorial@proactiveinvestors.com